Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Spectranetics settlement

This article was originally published in The Gray Sheet

Executive Summary

Excimer laser system maker Spectranetics will pay $4.9 million in civil damages plus a $100,000 forfeiture to resolve claims that it illegally imported and sold unapproved medical devices from overseas manufacturers, failed to meet clinical trial reporting requirements and promoted certain products for unapproved uses, the Justice Department announced Dec. 29. In addition to the civil settlement, the firm entered into a non-prosecution agreement and corporate integrity agreement to resolve the matter. According to the non-prosecution agreement, Spectranetics accepts responsibility for its conduct and will not be criminally prosecuted. As part of the integrity agreement, the firm's clinical trial records will be audited by an independent review organization "to insure compliance with FDA rules - including reporting of adverse events," HHS Inspector General Daniel Levinson said. FDA and U.S. Immigration and Customs Enforcement had served Spectranetics with a search warrant requesting information related to the matter in September 2008 (1"The Gray Sheet" Sept. 15, 2008)

Related Content

Former Spectranetics executives indicted
Spectranetics search warrant





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts